Skip to main content

Totaligent Closes Strategic Acqui-Hire of Aetherium Medical Platform

Written by Customer Service on . Posted in Mergers And Acquisitions.

Ivan Klarich Serves as President and Board Member; Transaction Completes Company’s Entry into High-Growth Biologics and Medical-Tourism Markets

BOCA RATON, Fla., May 20, 2026 (GLOBE NEWSWIRE) — Totaligent, Inc. (OTCID: TGNT) (“Totaligent” or “the Company”), an emerging leader in specialized infrastructure platform for the blossoming biologics space and intelligent business marketing data, today announced the successful closing of the previously announced Definitive Agreement with Ivan Klarich, founder of Aetherium Medical, for the strategic acqui-hire of the Aetherium Medical platform and team.

The transaction, which was executed via Definitive Agreement on April 15, 2026, provides Totaligent with full ownership and immediate operational access to Aetherium’s proprietary business plan, trade secrets, know-how, network contacts, operational infrastructure, and related intangible assets. Totaligent has formed a new wholly owned subsidiary, Aetherium Med One LLC, to which Klarich and the Aetherium team have contributed the Aetherium Assets.

Ivan Klarich will serve as President and on the Board of Directors of Totaligent following the closing.

“This closing represents the completion of a transformative milestone and positions Totaligent at the center of the convergence between explosive biologics innovation and the historic surge in Asia-Pacific medical tourism, now projected to reach $273.7 billion by 2032,” said Edward C. DeFeudis, CEO of Totaligent. “With the Aetherium platform fully operational, combined with our proprietary omni-channel digital marketing infrastructure and database, we have a first-mover advantage to connect breakthrough biologics to patients across APAC’s booming government-backed healthcare travel networks. We are moving swiftly to operationalize this infrastructure and advance the previously announced joint venture with GloMed Solutions, which is scheduled to close within the next week.”

The Aetherium platform serves as essential infrastructure connecting innovative biotechnology companies—particularly those advancing AI-enabled biologics and regenerative therapies—with global patients through ethical, efficient, and compliant medical-tourism channels in the Asia-Pacific region. Built on specialized cold-chain logistics, turnkey commercialization services, and robust ethical governance, Aetherium provides the foundational “picks-and-shovels” layer for the rapidly expanding biologics industry, with Japan’s progressive PMD Act regulatory framework serving as its geographic and regulatory cornerstone.

About Aetherium Medical Aetherium Medical is a specialized infrastructure platform that bridges innovative biotechnology companies—particularly those advancing AI-enabled biologic therapies—with global patients through ethical, efficient, and compliant medical-tourism channels in the Asia-Pacific region. The platform intends to leverage GloMed Solutions for specialized cold-chain logistics, turnkey commercialization services, and robust ethical governance, providing the foundational “picks-and-shovels” layer for the rapidly expanding biologics industry. For more information, visit https://www.aetheriummedical.com/.

About Totaligent, Inc. Totaligent, Inc. (OTCID: TGNT) is an innovative provider of omni-channel digital marketing solutions, specializing in targeted outreach to medical, pharmaceutical, and biotechnology professionals through its proprietary database of over one billion records. The Company is focused on strategic growth in high-potential sectors, including advanced biologics commercialization. For more information, visit www.totaligent.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Such risks include, but are not limited to, the ability to achieve performance milestones, successfully integrate the Aetherium Assets, negotiate and consummate any joint-venture or acquisition transactions (including with GloMed), secure necessary approvals, and execute the Company’s growth strategy. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statements.

Investor Relations
ir@totaligent.com
Ben Hansel
(720) 288-8495

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.